4/3/2018 PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION IN THE PATIENT WITH CKD TONI A. HARPS, APRN-CNS, MSN NEPHROLOGY WHY THIS TOPIC/OBJECTIVES
|
|
- Avis Goodman
- 5 years ago
- Views:
Transcription
1 PHARMACOLOGICAL MANAGEMENT OF HYPERTENSION IN THE PATIENT WITH CKD TONI A. HARPS, APRN-CNS, MSN NEPHROLOGY WHY THIS TOPIC/OBJECTIVES To identify Blood pressure (BP) medications which are used to manage Hypertension (HTN) in the adult patient with chronic kidney disease (CKD) Identify common and not so common issues associated with these medications, such as monitoring, adverse reactions, side effects, interactions, etc To identify primary systems which impact blood pressure Determine how to choose add on BP medications for CKD patients with co-morbidities Apply knowledge to everyday practice 2 WHAT IS HYPERTENSION Definition of Hypertension (HTN) Systolic Blood Pressure (SBP) > 140 and Diastolic Blood Pressure > 90 Classified as Essential HTN Commonly starting in the 5 th or 6 th decade of life Associated with increased salt intake, obesity, and some familiar components Secondary HTN is associated with Renal Artery Stenosis, Chronic Kidney Disease, Sleep Apnea and Adrenal diseases This Photo by Unknown Author is licensed under CC BY-NC-ND 3 1
2 WHAT IS HYPERTENSION Prevalence It is a global problem Major risk factor for Cardiovascular Disease (CVD) Impacts > 60% of adults older than 60 y.o. Responsible for 7.5million deaths per year globally In the United States HTN is associated with > $45million plus bill related to cost such as medication, health care services, workforce absentees it estimated over 1.5 billion adults will be diagnosed with HTN This Photo by Unknown Author is licensed under CC BY-NC-SA 4 PRIMARY SYSTEMS WHICH IMPACT BLOOD PRESSURE Sympathetic Nervous System (SNS) utilizes Alpha- adrenergic receptor impact blood vessels causing vasoconstriction Beta Adrenergic receptors impact the heart and blood vessels causing vasodilatation Of note, the Renal SNS is a key player in BP management This Photo by Unknown Author is licensed under CC BY-NC-SA The efferent pathway of the Kidney is a highway which moves signals between the SNS and the Kidneys activating the Renin-angiotensin-aldosterone system (RAAS) 5 PRIMARY SYSTEMS WHICH IMPACT BLOOD PRESSURE Renin-angiotensin-aldosterone system Stimulates renin which initiates a process which causes vasoconstriction Which works to retain sodium and water to increase blood pressure Endothelial (form the lining of the blood cells) Endothelial Dysfunction causes decreased nitric oxide (Nitric oxide causes vasodilatation) which plays a major role in regulating the tone of blood vessels This Photoby Unknown Author is licensed under CC BY-SA 6 2
3 WHAT IS CHRONIC KIDNEY DISEASE (CKD) CKD Decline in Glomerular Filtration Rate (GFR) <60 Presence of Kidney Damage for more than 3 months. CKD is staged according to Glomerular Filtration Rate (the rate of blood flow through the kidneys) Stage 1 > 90, Stage 2 (60-89), Stage 3 (30-59), Stage 4 (15-29), Stage 5 (< 15 or dialysis) Stage 1 and 2 have to be associated with some form of renal injury such as proteinuria to be considered CKD Albuminuria (Albumin or protein in the urine) Primary causes include HTN and Diabetes 7 This Photoby Unknown Author is licensed under CC BY-NC-SA WHAT IS CHRONIC KIDNEY DISEASE Chronic Kidney Disease (CKD) is on the rise Effecting > 25 million American Adults With > 600,000 progressing to End Stage Renal Disease Many will transition to dialysis or transplantation Patients with CKD are at increased risk for Cardio Vascular Disease (CVD) and death The diagnoses (Dx) responsible for the increased risk include uncontrolled HTN and Diabetes The risk increases with the declining function of the kidney 8 WHAT S THE CONNECTION So, which came first CKD or HTN? Hypertension can be the etiology or the result CKD Hypertension is major risk factor for CVD and CKD Patients with CKD are higher risk for HTN HTN is more common in pt s with CKD Strong relationship between HTN and Renal Artery Stenosis, Polycystic Disease, and Diabetic Nephropathy A primary goal of HTN management is to decrease progression of CKD 9 3
4 PHARMACOLOGICAL TREATMENT RECOMMENDATIONS Usually, pts with CKD require more than one BP medication to control HTN Pharmacological treatment recommendations for HTN in CKD include initiation with an Angiotensin Converting Enzyme Inhibitor (ACE I), Angiotensin Receptor Blockers (ARBs) Calcium Channel Blocker (CCB) or a diuretic Additional HTN medications are chosen according to the patient s other co-morbidities These BP medications include Calcium Channel Blocker, Beta Blockers, Aldosterone, Alpha-blockers, Vasodilators, Centrally Acting adrenergic inhibitors BP Goals for pts with CKD per JNC 8 is < 140/90 This Photoby Unknown Author is licensed under CC BY-NC- ND 10 PHARMACOLOGY OF ACE AND ARBS AND ITS IMPACT ON HTN Renin Angiotensin-aldosterone system (RAAS) is one of several primary systems which regulate HTN 4 Categories of medications which are used to regulate HTN in this system Angiotensin converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Aldosterone Agonist, Direct Renin inhibitors 11 PHARMACOLOGY OF ARBS AND ITS IMPACT ON HTN ACE I and ARBs work on the RAA system to inhibit or limit Angiotensin II development Angiotensin II impacts the vascular system causing vasoconstriction, increased aldosterone levels resulting in sodium and fluid retention Although these 2 classes of medications work on the same system, each class impacts at a separate target point ARBs work to block angiotensin II to angiotensin II type one ACE I work to Inhibit the conversion of angiotensin I into angiotensin II 12 This Photoby Unknown Author is licensed under CC BY 4
5 ARBS ARBS are not only efficacious in blood pressure management ( Candesartan, Irbesartan, Losartan, Olmesartan, Telmisartan, valsartan) ARBS are also a treatment recommendation to decrease left ventricular remodeling after myocardial infarction (MI), hinder development of diabetic neuropathy, decrease the risk for strokes, and decrease proteinuria etc. ARBs do not have the same coughing side effect associated with an ACE I ARBs start working in about 3-6 hours 13 ARBS Monitor K+ levels in these pts Avoid taking Lithium and ARBs together as ARBs cause increase renal reabsorption of Lithium Digoxin and Telmisartan taken together increase dig levels and may result in dig toxicity Telmisartan is the longest acting in the group with a 24 hr half-life Can be used with other BP meds and diuretics Usually well tolerated Beneficial in CKD with proteinuria 14 ACE INHIBITORS Decreases renal excretion of protein in the urine slowing progression to ESRD Can be used with other BP meds and diuretics Usually well tolerated Associated side effect non-dose dependent coughing and angio-edema minimally seen in Asian and African Americans (AA) More effective in Caucasians as RAA system is less pronounced in the AA Beneficial in CKD with proteinuria, Left Ventricular systolic dysfunction and post MI 15 5
6 CALCIUM CHANNEL BLOCKERS Non-dihydropyridines (1 st generation) work by decreasing heart rate and force of heart contraction Verapamil, Diltiazem (has more vasodilator action, and works better for management of HTN) Short acting Peripheral edema Reflex tachycardia Skin reactions Also Beneficial in decreasing the risk of stroke in pts with HTN 16 CALCIUM CHANNEL BLOCKERS Dihydropyridine (2 nd generation) CCBS decrease BP primarily through direct vasodilatation and are more suited for HTN management Contraindicated in pt with Congestive Heart Failure (CCBs may cause bradycardia) Amlodipine, Felodipine, Nicardipine, Nifedipine, More favorable profile such as absorption, distribution, and impact on the body For example amlodipine has a half life of hrs and takes about 8-10 hrs to peak effect 17 CALCIUM CHANNEL BLOCKERS Can be used with ACE or ARBs Recommended by the European guidelines for AA and elderly patients with isolated systolic hypertension Caution when combining Non-dihydropyridines with Beta Blocker in pt with heart failure CCBs may cause bradycardia 18 6
7 DIURETICS -LOOP Furosemide (Oral) Used to manage edema through excretion of Na and water from the kidneys BID dosing Bioavailability is extremely variable (10 90%) Take before meals to increase bioavailability Peaks in about 1 1.5hrs 19 This Photo by Unknown Author is licensed under CC BY-SA DIURETICS -LOOP Pt with renal dysfunction have a decreased response and increased plasma half-life r/t decreased urinary excretion It is recommended to use loop diuretics in pts with egfr < 30 or stage 4 CKD Torsemide effects of low doses improve with nighttime dosing -really!!!!! Daily dosing Half-life is 3-4 hrs 20 DIURETICS -LOOP Major Adverse Events associated with Furosemide Hypovolemia Electrolyte imbalance r/t to diuresis hypokalemia, hypomagnesemia, hypocalcemia, hyponatremia, hyperuricemia Hypersensitivity Furosemide is a sulfur based medication and cause allergic or hypersensitivity reactions (rash or acute interstitial nephritis) 21 7
8 DIURETICS -LOOP An alternative to furosemide is ethacrynic acid (a loop diuretic) w/o sulfur but has shown to be more ototoxic Furosemide can displace warfarin, meaning a lower dose of warfarin maybe needed Furosemide induced hypokalemia increases the risk of digitalis-induced arrhythmia Furosemide can increase risk of gout when given with cyclosporine which decreases renal urine excretion Ototoxicity 22 DIURETICS -THIAZIDES Thiazides Chlorothiazide, Hydrochlorothiazide (HCTZ), Metolazone, Chlorthalidone and indapamide Work to increase Na excretion in the urine Resulting in decreased extracellular volume, venous return and in the end decreased cardiac output Inexpensive 23 DIURETICS -THIAZIDES Keep in mind volume overload is a major contributor to HTN in the pt with CKD With declining GFR, less sodium (Na) is filtered resulting in fluid retention JNC7 recommended changing from thiazide to a loop diuretic when egfr is <30, JNC8 made no recommendations Many providers change to a loop diuretic when the pt reaches stage 4 of CKD 24 8
9 DIURETICS MINERALOCORTICOID RECEPTOR ANTAGONIST Spironolactone/Aldactone (mineralocorticoid receptor antagonist family) Very helpful when used in combination with and ACE, ARB, CCB or Diuretic Especially in the management of Heart Failure (blocks Aldosterone which causes fluid and Na retention) Works by inhibiting sodium potassium exchange and inhibits aldosterone-induced vasoconstriction Spironolactone is also known to reduce proteinuria by 61% in proteinuric kidney disease and decrease albuminuria by 60% Common problems associated with its use include gynecomastia, electrolyte imbalances such as hyperkalemia Electrolyte imbalances and hyperkalemia are more common in the pt who already has CKD and are on an ACE or ARB 25 BETA BLOCKERS Beta Blockers (BB) are the go to when treating history of MI and heart failure Carvedilol bid dosing and Metoprolol daily, Bisoprolol daily BB work to decrease cardiac output and decrease renal renin secretion BB alter glucose metabolism and mask hypoglycemia BB are also associated with depression, fatigue and sexual dysfunction 26 ALPHA-BLOCKER Are usually used as an add on or maybe used for the pt who cannot tolerate other first line BP meds Doxazosin (Cardura), Prazosin (Minipress), Terazosin Alpha-Blockers work to cause vasodilatation Primary problems associated with AB include first dose syncope and vasovagal syncope please caution pt Using with a diuretic increases the total impact on BP Very helpful when treating HTN in the older male with benign prostate hypertrophy (BPH) 27 9
10 MISCELLANEOUS Vasodilators -Hydralazine / TID dosing/2 nd line of medication/used along with other medications Central Agonist Clonidine/use with other meds/works in the central nervous system/may cause drowsiness Nitrate Isosorbide/used for chest pain and can be used for HTN/dizziness with position change 28 CASE SCENARIO JD a 75 y.o. AA male was referred to CKD clinic for SCr of 2.2 and HTN Dx include CKD, HLD, OA, OSA, HTN, Diab Exam findings: 20 yr hx of Diab, and HTN, CKD 5yrs, with egfr of 29, and +2 LE edema Home sys bp 140s- 170s, C/o difficulty starting stream, A1c ave.6.5% No proteinuria, Electrolytes within normal range Current BP meds include Amlodipine (Norvasc) 10mg every morning, HTCZ 25mg qd What BP medications would be most helpful considering pt s co-morbidities? 29 RECOMMENDATIONS Terazosin for BPH and it BP lowering properties Change HCTZ to Furosemide 20mg as pt with egfr <
11 CASE SCENARIO DJ a 75 y.o. male was referred to CKD clinic for SCr of 1.7 and uncontrolled HTN Dx include CKD, HLD, OA, OSA, HTN, Diab Exam findings: 20 yr hx of Diab, and HTN, CKD 10yrs, with egfr of 38, and +3 LE edema, No hx of MI Home sys bp 140s- 170s, Heart Rate , A1C ave.9.5%, Moderate proteinuria 1.5 grams for 2 years Electrolytes within normal range, K+ is 5.0 Current BP meds include Amlodipine 10mg every morning, Spironolactone (Aldactone) 50mg qd, Carvedilol 6.25mg daily, Lisinopril 20mg qd What BP medications would be most helpful considering pt s co-morbidities? 31 RECOMMENDATIONS Increase carvedilol to bid as dosing recommendation is bid to address tachycardia Keep lisinopril to address proteinuria Change Spironolactone to Furosemide as pt s CKD is at stage 3 and this will also address slightly elevated K+ level and edema 32 CASE SCENARIO TH a 75 y.o. male was referred to CKD clinic for SCr of 1.8 and HTN Dx include CKD, HLD, OA, OSA, HTN, Diab, Exam findings: 20 yr hx of Diab, and HTN, CKD 10yrs, with egfr of 38, and +3 LE edema Home sys bp 140s- 170s, A1C ave. 6.5%, Moderate proteinuria 1.5 grams for 2 years, MI 3 weeks ago Persistent cough for last few months Electrolytes within normal range Current BP meds include Lisinopril 30 mg daily, Carvedilol 6.25mg bid, Furosemide 40mg daily What BP medications would be most helpful considering pt s co-morbidities? 33 11
12 RECOMMENDATIONS Increase Furosemide Immediately stop Lisinopril r/t persistent cough Start Losartan as it does not have the side effects of coughing and possible angioedema 34 OVERVIEW Cornerstone for BP management for the pt with CKD is an ACE I or an ARB with a diuretic There are settings in which a ACE I or ARB may not be used Evaluation of pt s other co-morbidities should be used in the equation identifying add on bp meds 35 Abraham, H. M. A., White, C. M., & White, W. B. (2015). The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases.Drug Safety,38(1), Arjun, S. & Agarwa;.R. (2015). Thiazide diuretics in Chronic Kidney Disease. Curr Hypertension Rep. 17, Doi: /s x Delacroix, et al., J (2014), Hypertension: Pathophysiology and Treatement. Neurol Neurophysiol, 5: Dézsi, C. A. (2014). Differences in the Clinical Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Critical Review of the Evidence.American Journal of Cardiovascular Drugs,14(3), Frohlich, H., Nelges, C., Tager, t., Schwenger, V., Schnorbach, J., Cebola, r., Schnorbach, J.,... Frankenstein, L. (2016). Longterm changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease, http//dx.doi.org/ /j.ahj
13 Judd, E., & Calhoun, D. A. (2015). Management of Hypertension in CKD: Beyond the Guidelines.Advances in Chronic Kidney Disease, 22(2), Norris, K. C., & Nicholas, S. B. (2015). Strategies for Controlling Blood Pressure and Reducing Cardiovascular Disease Risk in Patients with Chronic Kidney Disease.Ethnicity & Disease,25(4), Oh, S. W., & Han, S. Y. (2015). Loop Diuretics in Clinical Practice.Electrolytes & Blood Pressure : E & BP,13(1), Park M, Hsu C. An ACE in the Hole for Patients With Advanced Chronic Kidney Disease?.JAMA Intern Med.2014;174(3): doi: /jamainternmed Park M, Hsu C. An ACE in the Hole for Patients With Advanced Chronic Kidney Disease?.JAMA Intern Med.2014;174(3): doi: /jamainternmed Roush, G., & Sica, D. (2016). Diuretics for hypertension: a review and update. American Journal of Hypertension, 29, Doi: /ajh/hpw030 Tedla, F. M., Brar, A., Browne, R., & Brown, C. (2011). Hypertension in Chronic Kidney Disease: Navigating the Evidence.International Journal of Hypertension, 2011, Tomiyama, Hirofumi and Yamashina, Akira, Beta-Blockers in the Management of Hypertension and/or Chronic Kidney Disease, International Journal of Hypertension, vol. 2014, Article ID , 7 pages, doi: /2014/919256ca Tocci, G., Battistoni, A., Passerini, J., Musumeci, M., Francia, P., Ferrucci, A.& Volpe, M. (2014). Calcium Channel Blockers and Hypertension. Journal of Cardiology, 20, Doi: / Viazzi, F., Bonino, B., Cappadona, F. & Pontremoli, R. (2016). Reinin-angiotension-aldosterone system blockade in chronic kidney disease: current statagies and a look ahead. International Emergency Medicine, 11, Doi: /s THE END nurseth333@gmail.com 39 13
Hypertension (JNC-8)
Hypertension (JNC-8) Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 17, 2018, presented by Ezra Levy, Pharm.D.! The 8 th Joint
More informationIntroductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs
Introductory Clinical Pharmacology Chapter 41 Antihypertensive Drugs Blood Pressure Normal = sys
More informationAntihypertensive drugs SUMMARY Made by: Lama Shatat
Antihypertensive drugs SUMMARY Made by: Lama Shatat Diuretic Thiazide diuretics The loop diuretics Potassium-sparing Diuretics *Hydrochlorothiazide *Chlorthalidone *Furosemide *Torsemide *Bumetanide Aldosterone
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationHypertension Update. Objectives 4/28/2015. Beverly J. Mathis, D.O. OOA May 2015
Hypertension Update Beverly J. Mathis, D.O. OOA May 2015 Objectives Learn new recommendations for BP treatment goals Approach to hypertension in the office Use of hypertensive drugs, and how to tailor
More information7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension
Prevalence of Hypertension Hypertension: Diagnosis and Management T. Villela, M.D. Program Director University of California, San Francisco-San Francisco General Hospital Family and Community Medicine
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationHypertensionTreatment Guidelines. Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC
HypertensionTreatment Guidelines Michaelene Urban APRN, MSN, ACNS-BC, ANP-BC Objectives: Review the definition of the different stages of HTN. Review the current guidelines for treatment of HTN. Provided
More informationChapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories
Chapter 23 Drugs for Hypertension Slide 37 Slide 41 Media Directory Nifedipine Animation Doxazosin Animation Upper Saddle River, New Jersey 07458 All rights reserved. Cardiovascular Disease (CVD) Includes
More informationCOMPLEX HYPERTENSION. Anita Ralstin, FNP-BC Next Step Health Consultant, LLC
COMPLEX HYPERTENSION Anita Ralstin, FNP-BC Next Step Health Consultant, LLC Incidence Of Hypertension About 70 million American adults have high blood pressure. About 33% of the population Only 52% have
More informationAntihypertensives. Antihypertensive Classes. RAAS Inhibitors. Renin-Angiotensin Cascade. Angiotensin Receptors. Approaches to Hypertension Treatment
Approaches to Hypertension Treatment Antihypertensives Inhibit Sympathetic impulses Inhibit contractility Inhibit heart rate Inhibit vasoconstriction Inhibit smooth muscle function Inhibit RAAS Inhibit
More informationManaging Hypertension in Diabetes Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park.
Managing Hypertension in Diabetes 2015 Sean Stewart, PharmD, BCPS, BCACP, CLS Internal Medicine Park Nicollet Clinic St Louis Park Case Scenario Mike M is a 59 year old man with type 2 diabetes managed
More informationDifficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment
Difficult to Control HTN: It is not all the same. Structured approach to evaluation and treatment Dmitri Vasin M.D. Nephrologist and ASH certified clinical hypertension specialist Bremerton, WA, USA Johnson
More informationManagement of Hypertension
Clinical Practice Guidelines Management of Hypertension Definition and classification of blood pressure levels (mmhg) Category Systolic Diastolic Normal
More informationHypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy
Hypertension Update Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy Introduction 1/3 of US adults have HTN More prevalent in non-hispanic
More informationSection 3, Lecture 2
59-291 Section 3, Lecture 2 Diuretics: -increase in Na + excretion (naturesis) Thiazide and Related diuretics -decreased PVR due to decreases muscle contraction -an economical and effective treatment -protect
More informationWhat in the World is Functional Medicine?
What in the World is Functional Medicine? An Introduction to a Systems Based Approach of Chronic Disease Meneah R Haworth, FNP-C Disclosure v I am a student of the Institute for Functional Medicine. They
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationManagement of Hypertension. M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine
Management of Hypertension M Misra MD MRCP (UK) Division of Nephrology University of Missouri School of Medicine Disturbing Trends in Hypertension HTN awareness, treatment and control rates are decreasing
More informationsympatholytics sympatholytics sympatholytics
sympatholytics sympatholytics sympatholytics CNS-ACTING SYMPATHOPLEGICS Sympathetic brain signals Doesn t affect baroreceptor reflex (no orthostatic hypotension) Methyldopa α-methylne crosses BBB (+) α-adrenoreceptors
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationAntihypertensive Agents
Antihypertensive Agents Southern California University of Health Sciences Physician Assistant Program Management and Treatment of Hypertension April 7, 08, presented by Ezra Levy, Pharm.D! Usual Dose,
More informationHeart failure. Failure? blood supply insufficient for body needs. CHF = congestive heart failure. increased blood volume, interstitial fluid
Failure? blood supply insufficient for body needs CHF = congestive heart failure increased blood volume, interstitial fluid Underlying causes/risk factors Ischemic heart disease (CAD) 70% hypertension
More informationTowards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:
Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood: Cardiac Output (CO) CO=SVxHR (stroke volume x heart rate) Cardiac output: The amount of blood
More information만성콩팥병환자에서의혈압관리 분당서울대병원신장내과 안신영
만성콩팥병환자에서의혈압관리 분당서울대병원신장내과 안신영 Contents Introduction Lifestyle and Pharmacological Tx CKD ND ptswithout diabetes CKD ND ptswith diabetes In elderly ptswith CKD ND 2013 대한고혈압학회진료지침 JNC 8th Introduction
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationCombining Antihypertensives in People with Diabetes
Combining ntihypertensives in People with Diabetes The majority of people with diabetes will develop hypertension and this subsequently increases the risk of microvascular and macrovascular complications.
More informationHYPERTENSION: Sustained elevation of arterial blood pressure above normal o Systolic 140 mm Hg and/or o Diastolic 90 mm Hg
Lecture 39 Anti-Hypertensives B-Rod BLOOD PRESSURE: Systolic / Diastolic NORMAL: 120/80 Systolic = measure of pressure as heart is beating Diastolic = measure of pressure while heart is at rest between
More informationM2 TEACHING UNDERSTANDING PHARMACOLOGY
M2 TEACHING UNDERSTANDING PHARMACOLOGY USING CVS SYSTEM AS AN EXAMPLE NIGEL FONG 2 JAN 2014 TODAY S OBJECTIVE Pharmacology often seems like an endless list of mechanisms and side effects to memorize. To
More information8/20/2018. Objectives. What is hypertension? cont. What is hypertension? Epidemiology cont. Epidemiology
Objectives Hypertension (high blood pressure): Clinical Pearls for the Pharmacy Technician Tanya Schmidt PharmD, RPh Director of Central Operations at Thrifty White Pharmacy North Dakota Board of Pharmacy
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationANTI- HYPERTENSIVE AGENTS
CLINICAL ANTI- HYPERTENSIVE AGENTS Jacqueline van Schoor, MPharm, BSc (Hons) Amayeza Info Centre Hypertension represents a major public health concern. It affects about a billion people worldwide and is
More informationHEART FAILURE PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
HEART FAILURE PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Understand the effects of heart failure in the body
More informationDr Narender Goel MD (Internal Medicine and Nephrology) Financial Disclosure: None, Conflict of Interest: None
Dr Narender Goel MD (Internal Medicine and Nephrology) drnarendergoel@gmail.com Financial Disclosure: None, Conflict of Interest: None 12 th December 2013, New York Visit us at: http://kidneyscience.info/
More informationNetwork Hypertension Algorithm
Network Hypertension Algorithm Content Review and Approval: This document is subject to review, revision, and (re)approval by the Clinical Integration and Oversight Committee (CIOC) annually and following
More informationHYPERTENSION IN CKD. LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL
HYPERTENSION IN CKD LEENA ONGAJYOOTH, M.D., Dr.med RENAL UNIT SIRIRAJ HOSPITAL Stages in Progression of Chronic Kidney Disease and Therapeutic Strategies Complications Normal Increased risk Damage GFR
More informationStages of Chronic Kidney Disease (CKD)
Early Treatment is the Key Stages of Chronic Kidney Disease (CKD) Stage Description GFR (ml/min/1.73 m 2 ) >90 1 Kidney damage with normal or GFR 2 Mild decrease in GFR 60-89 3 Moderate decrease in GFR
More informationHypertension Update Clinical Controversies Regarding Age and Race
Hypertension Update Clinical Controversies Regarding Age and Race Allison Helmer, PharmD, BCACP Assistant Clinical Professor Auburn University Harrison School of Pharmacy July 22, 2017 DISCLOSURE/CONFLICT
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationChapter 10 Worksheet Blood Pressure and Antithrombotic Agents
Complete the following. 1. A layer of cells lines each vessel in the vascular system. This layer is a passive barrier that keeps cells and proteins from going into tissues; it also contains substances
More informationManagement of High Blood Pressure in Adults
Management of High Blood Pressure in Adults Based on the Report from the Panel Members Appointed to the Eighth Joint National Committee (JNC8) James, P. A. (2014, February 05). 2014 Guideline for Management
More informationBeta 1 Beta blockers A - Propranolol,
Pharma Lecture 3 Beta blockers that we are most interested in are the ones that target Beta 1 receptors. Beta blockers A - Propranolol, it s a non-selective competitive antagonist of beta 1 and beta 2
More informationHYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP
HYPERTENSION IN EMERGENCY MEDICINE Michael Jay Bresler, M.D., FACEP What is normal blood pressure? Prehypertension 130-139/80-90 Compared with normal BP Double the risk for developing hypertension. Lifestyle
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationHypertension: Update
Hypertension: Update Meenakshi A Bhalla MD,FACC Associate Professor of Medicine Director Preventive Cardiology Advanced Heart Failure and Transplant Cardiology University of Kentucky Faculty Disclosure
More informationHypertension Pharmacotherapy: A Practical Approach
Hypertension Pharmacotherapy: A Practical Approach Ronald Victor, MD Burns & Allen Chair in Cardiology Director, The Hypertension Center Associate Director, The Heart Institute Hypertension Center 1. 2.
More informationHypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, Financial Disclosures
Hypertension Guidelines: Are We Pressured to Change? Oregon Cardiovascular Symposium Portland, Oregon June 6, 2015 William C. Cushman, MD Professor, Preventive Medicine, Medicine, and Physiology University
More informationDifficult-to-Control & Resistant Hypertension. Anthony Viera, MD, MPH, FAHA Professor and Chair
Difficult-to-Control & Resistant Hypertension Anthony Viera, MD, MPH, FAHA Professor and Chair Objectives Define resistant hypertension Discuss evaluation strategy for patient with HTN that appears difficult
More informationTreatment of Essential Hypertension
2016 edition by Mark A. Simmons, PhD Department of Pharmaceutical Sciences School of Pharmacy University of Maryland Eastern Shore Originally developed by Hugh J. Burford, PhD, FCP Department of Pharmacology
More informationHypertension Management - Summary
Who should have blood pressure assessed? Hypertension Management - Summary All patients over the age of 40 years, every 1-3 years in order to determine their cardiovascular risk (ie. Framingham Risk Score)
More informationAdult Blood Pressure Clinician Guide June 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Blood Pressure Clinician Guide June 2018 Adult Blood Pressure Clinician Guide June 2018 Introduction This Clinician Guide is based on the 2018
More informationHypertension CHAPTER-I CARDIOVASCULAR SYSTEM. Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati
CHAPTER-I CARDIOVASCULAR SYSTEM Hypertension SUB: PHARMACOTHERAPEUTICS-I CODE:T0820006 Dr. K T NAIK Pharm.D Associate Professor Department of Pharm.D Krishna Teja Pharmacy College, Tirupati Hypertension
More informationMODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure. No relevant financial relationships. Blood Pressure and Risk
MODERN MANAGEMENT OF HYPERTENSION Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More informationManaging Hypertension in 2016
Managing Hypertension in 2016: Where Do We Draw the Line? Disclosure No relevant financial relationships Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu
More information2014 HYPERTENSION GUIDELINES
2014 HYPERTENSION GUIDELINES Eileen M. Twomey, Pharm.D., BCPS 1 Learning Objectives Describe specific blood pressure thresholds at which antihypertensive therapy should be initiated and blood pressure
More informationBy Prof. Khaled El-Rabat
What is The Optimum? By Prof. Khaled El-Rabat Professor of Cardiology - Benha Faculty of Medicine HT. Introduction Despite major worldwide efforts over recent decades directed at diagnosing and treating
More informationHypertension diagnosis (see detail document) Diabetic. Target less than 130/80mmHg
Hypertension diagnosis (see detail document) Non-diabetic Diabetic Very elderly (older than 80 years) Target less than 140/90mmHg Target less than 130/80mmHg Consider SBP target less than 150mmHg Non-diabetic
More informationTherapeutics of Diuretics
(Last Updated: 08/22/2018) Created by: Socco, Samantha Therapeutics of Diuretics Thambi, M. (2017). The Clinical Use of Diuretics. Lecture presented at PHAR 503 Lecture in UIC College of Pharmacy, Chicago.
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationYounger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.
Appendix 2A - Guidance on Management of Hypertension Measurement of blood pressure All adults from 40 years should have blood pressure measured as part of opportunistic cardiovascular risk assessment.
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Prevalence 29%; Blacks 33.5% About 72.5% treated; 53.5% uncontrolled (>140/90) Risk for poor control: Latinos, Blacks, age 18-44 and 80,
More informationMEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION
MEDICAL MANAGEMENT OF PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION FRANCIS X. CELIS, D.O. OPSO FALL CONFERENCE PORTLAND, OR 16 SEPTEMBER 2017 OVERVIEW What are the ACC/AHA Stages of HF? What
More informationHypertension Management: A Moving Target
9:45 :30am Hypertension Management: A Moving Target SPEAKER Karol Watson, MD, PhD, FACC Presenter Disclosure Information The following relationships exist related to this presentation: Karol E. Watson,
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationDISCLOSURES OUTLINE OUTLINE 9/29/2014 ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE
ANTI-HYPERTENSIVE MANAGEMENT OF CHRONIC KIDNEY DISEASE DISCLOSURES Editor-in-Chief- Nephrology- UpToDate- (Wolters Klewer) Richard J. Glassock, MD, MACP Geffen School of Medicine at UCLA 1 st Annual Internal
More informationHypertension and the 2017 Guidelines Meeting the Targets in Small Groups. Lisa Ivy APRN
Hypertension and the 2017 Guidelines Meeting the Targets in Small Groups Lisa Ivy APRN The 2017 Guideline is an Update to JNC7 New information regarding BP related risk of CVD Ambulatory BP monitoring
More informationLESSON ASSIGNMENT. After completing this lesson you will be able to:
LESSON ASSIGNMENT SUBCOURSE MD0806 LESSON 7 Therapeutics III. Antihypertensive Agents. LESSON ASSIGNMENT Paragraphs 7-1--7-12. LESSON OBJECTIVES After completing this lesson you will be able to: 7-1. From
More informationPreventing and Treating High Blood Pressure
Preventing and Treating High Blood Pressure: Finding the Right Balance of Integrative and Pharmacologic Approaches Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Blood Pressure
More informationWhat s In the New Hypertension Guidelines?
American College of Physicians Ohio/Air Force Chapters 2018 Scientific Meeting Columbus, OH October 5, 2018 What s In the New Hypertension Guidelines? Max C. Reif, MD, FACP Objectives: At the end of the
More informationWe are delighted to have Dr. Roetzheim with us today to discuss Managing Hypertension in Older Adult Patients.
Richard Roetzheim, MD, MSPH is Professor and Chair, Department of Family Medicine at the University of South Florida Morsani College of Medicine. Dr. Roetzheim has considerable experience leading NIH funded
More informationModern Management of Hypertension
Modern Management of Hypertension Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Hypertension Prevalence
More informationADVANCES IN MANAGEMENT OF HYPERTENSION
Advances in Management of Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Current Status of Prevalence 29%; Blacks 33.5%
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationAntihypertensives. Diagnostic category
Measurement of blood pressure At first assessment, take both arms then choose the one with the higher reading. Beware of orthostatic hypotension. Measure BP in sitting position, and repeat after patient
More informationTreating Hypertension from
Treating Hypertension from Initiation to Resistance: A Case Study Approach Michelle Krause, MD Division of Nephrology University of Arkansas for Medical Sciences Central Arkansas Veteran s Healthcare System
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHypertension Update Warwick Jaffe Interventional Cardiologist Ascot Hospital
Hypertension Update 2008 Warwick Jaffe Interventional Cardiologist Ascot Hospital Definition of Hypertension Continuous variable At some point the risk becomes high enough to justify treatment Treatment
More informationPharmacology I [PHL 313] Diuretics. Dr. Mohammad Nazam Ansari
Pharmacology I [PHL 313] Diuretics Dr. Mohammad Nazam Ansari Renal Pharmacology Kidneys: Each adult kidney weighs 125-170g in males and 115-155g in females, represent 0.5% of total body weight, but receive
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationCategories of HTN. Overview of Hypertension. Types of Hypertension
Categories of HTN Overview of Hypertension Normal SBP 100 Quick review of the Basics: What is
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationDRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI
DRUGS USED TO TREAT HYPERTENSION BY ALI ALALAWI 3. Vasodilators Drugs which dilate blood vessels ( decrease peripheral vascular resistance) by acting on smooth muscle cells through non-autonomic mechanisms:
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationMedical Translation: Welcome to our webinar
r Welcome to our webinar Medical Translation: The Pharmacodynamics and Physiological Effects of Drug Classes Commonly Studied during Clinical Trials with Carmen Cross 13 February 2014 www.ecpdwebinars.co.uk
More informationBlood pressure (BP) control. Hypertension
Blood pressure (BP) control Normal heart function Blood pressure (BP) control blood pressure (BP) cardiac output (CO) = total peripheral resistance (TPR) heart rate (HR) filling pressure arteriolar volume
More informationTop 200 Section 4. Cardiovascular Drugs
Top 200 Section 4 Cardiovascular Drugs Objectives After finishing this presentation the audience should be able to: Describe conditions/disease states that would make a person a candidate for drug therapy.
More informationANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR.
ANGIOTENSIN II RECEPTOR BLOCKERS: MORE THAN THE ALTERNATIVE PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP RENIN-ANGIOTENSIN
More informationDisclosures. Learning Objectives. Hypertension: a sprint to the finish Ontario Pharmacists Association 1
Disclosures I have no current or past relationships with commercial entities I have received a speaker s fee from the Ontario Pharmacists Association for this learning activity Laura Tsang PharmD Sunnybrook
More informationSTANDARD treatment algorithm mmHg
STANDARD treatment algorithm 130-140mmHg (i) At BASELINE, If AVERAGE SBP 1 > 140mmHg If on no antihypertensive drugs: Start 1 drug: If >55 years old / Afro-Caribbean: Calcium channel blocker (CCB) 2 If
More informationCombination Therapy for Hypertension
Combination Therapy for Hypertension Se-Joong Rim, MD Cardiology Division, Yonsei University College of Medicine, Seoul, Korea Goals of Therapy Reduce CVD and renal morbidity and mortality. Treat to BP
More informationHow to approach resistant hypertension. Teh-Li Huo, M.D., Ph.D.
How to approach resistant hypertension Teh-Li Huo, M.D., Ph.D. BP goals No risk factors:
More informationGuide to the New Hypertension Guidelines
Guide to the New Hypertension Guidelines LCDR J. Garrett Sims, PharmD, BCPS Advanced Practice Pharmacist Crow/Northern Cheyenne Hospital Hypertension St Disclosures None Objectives Describe the new hypertension
More informationModern Management of Hypertension: Where Do We Draw the Line?
Modern Management of Hypertension: Where Do We Draw the Line? Robert B. Baron MD Professor of Medicine Associate Dean for GME and CME Declaration of full disclosure: No conflict of interest Blood Pressure
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationβ adrenergic blockade, a renal perspective Prof S O McLigeyo
β adrenergic blockade, a renal perspective Prof S O McLigeyo Carvedilol Third generation β blocker (both β 1 and β 2 ) Possesses α 1 adrenergic blocking properties. β: α blocking ratio 7:1 to 3:1 Antioxidant
More informationDiuretics (Saluretics)
Diuretics (Saluretics) Diuretics increase urine excretion mainly by reabsorption of salts and water from kidney tubules These agents are ion transport inhibitors that decrease the reabsorption of Na+ at
More informationVA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERENCE CARDS Chronic Kidney Disease
VA/DoD Clinical Practice Guideline for the Management of Chronic Kidney Disease in Primary Care (2008) PROVIDER REFERECE CARDS Chronic Kidney Disease CKD VA/DoD Clinical Practice Guideline for the Management
More information